For adults with fatty liver disease, eating all meals within an 8-hour window each day improves fasting blood sugar levels more than spreading the same meals throughout the day, even when total food intake is unchanged.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether 16:8 TRE consistently improves fasting glucose in MASLD across populations, accounting for baseline insulin resistance, medication use, and adherence patterns.
A systematic review and meta-analysis of all RCTs comparing 16:8 TRE versus isocaloric standard eating in adults with MASLD, including at least 12 studies with 800+ participants total, measuring fasting glucose and HOMA-IR as primary outcomes over 8–24 weeks.
Whether 16:8 TRE causes sustained reduction in fasting glucose over 24 weeks in MASLD patients with prediabetes, independent of weight change.
A multicenter, double-blind RCT of 180 adults with MASLD and prediabetes (HbA1c 5.7–6.4%), randomized to 16:8 TRE or matched-calorie standard eating for 24 weeks, with fasting glucose and HOMA-IR measured at baseline, 12, and 24 weeks, and weight change as a covariate.
Whether adults with MASLD who adopt 16:8 TRE over 5 years have lower incidence of type 2 diabetes compared to those who follow standard eating.
A prospective cohort study following 1,000 adults with MASLD and prediabetes for 5 years, stratified by adherence to 16:8 TRE (≥75% days), measuring annual fasting glucose, HbA1c, and incident diabetes, adjusting for BMI, physical activity, and medication use.
Whether individuals with MASLD who developed type 2 diabetes over 3 years were less likely to have practiced 16:8 TRE compared to those who remained normoglycemic.
A case-control study comparing 150 MASLD patients who developed type 2 diabetes within 3 years to 150 matched controls who remained normoglycemic, assessing prior adherence to 16:8 TRE via structured dietary recall and wearable data.
Whether adults with MASLD currently practicing 16:8 TRE have lower fasting glucose than those not practicing it, in a representative population.
A cross-sectional survey of 1,200 adults with MASLD, measuring current TRE adherence and fasting glucose via standardized clinic measurement, adjusting for age, sex, BMI, and antidiabetic medication use.